WhaleWatch

DATE17 Aug

NIFTY 24,288 ▼ 0.32%BANK NIFTY 57,498 ▲ 0.01%NIFTY IT 30,808 ▼ 1.75%NIFTY PHARMA 26,342 ▼ 0.39%SCHNEIDER 1,212 ▼ 11.47%IPCALAB 1,885 ▲ 8.67%HINDCOPPER 573 ▲ 8.24%PTCIL 20,584 ▲ 8.05%BELRISE 236 ▼ 7.54%GPIL 251 ▲ 6.54%NSLNISP 42 ▼ 6.16%INOXWIND 78 ▲ 6.05%FINCABLES 1,321 ▲ 5.93%MOTILALOFS 955 ▲ 5.68%NIFTY 24,288 ▼ 0.32%BANK NIFTY 57,498 ▲ 0.01%NIFTY IT 30,808 ▼ 1.75%NIFTY PHARMA 26,342 ▼ 0.39%SCHNEIDER 1,212 ▼ 11.47%IPCALAB 1,885 ▲ 8.67%HINDCOPPER 573 ▲ 8.24%PTCIL 20,584 ▲ 8.05%BELRISE 236 ▼ 7.54%GPIL 251 ▲ 6.54%NSLNISP 42 ▼ 6.16%INOXWIND 78 ▲ 6.05%FINCABLES 1,321 ▲ 5.93%MOTILALOFS 955 ▲ 5.68%

Morning brief · Tuesday, 18 August 2026

Morepen Labs’ 90 percent rally runs into an identity crisis

Market pulse

Indian markets ended a mixed session as a steep nearly two percent fall in the IT index dragged the Nifty down to 24,288, even as banking stocks finished flat. Individual stocks saw sharp moves, with Ipca Labs and Hindcopper surging over eight percent while Schneider Electric plunged more than eleven percent.

From the investor's mind

One post worth your time, explained

@aditya_kondawar · on X

Aditya Kondawar highlights the significant expansion of India's alternative investment space, encompassing Alternative Investment Funds (AIFs) and Portfolio Management Services (PMS), which has grown at a CAGR exceeding 31% over the last decade. This surge has led to the sector's Assets Under Management (AUM) surpassing ₹25 lakh crore by March 2026. The growth is primarily propelled by Category II AIFs, which include private equity, venture capital, and debt funds, demonstrating an approximate 45% CAGR, largely driven by investments from institutions and High Net Worth Individuals (HNIs).

Word in the street

What the wider market is buzzing about

Morepen Laboratories Limited

₹90Past year ▲ 88%M.cap ₹4,922 Cr

A nearly 90 percent rise in a year has put Morepen Laboratories on the investor radar, though not without some debate. The company, now commanding a market capitalisation of about 4,922 crore, has sparked a discussion about its business model. Investors are questioning whether Morepen is a contract development and manufacturing organisation, or CDMO, a term used by its promoter and in some media, or simply a contract manufacturing organisation, or CMO. Some see the delivery timelines as more indicative of a CMO. While this could still suggest its capabilities are valued, the path to higher value is a subject of speculation. If the company can achieve better margins, it may indeed be inching upwards.

Know more about the stock

Yesterday's big moves